Literature DB >> 6345180

Interferons as macrophage-activating factors. II. Enhanced secretion of interleukin 1 by lipopolysaccharide-stimulated human monocytes.

F Arenzana-Seisdedos, J L Virelizier.   

Abstract

Human adherent monocytes were incubated with interferon (IFN) preparations, then washed and stimulated with endotoxins. The interleukin (IL1) activity in the supernatants of IFN-treated monocyte cultures was found to be increased as compared to control (not pretreated) cultures. This phenomenon was observed whether alpha or beta IFN was used, and was completely abolished by antiserum to the relevant IFN. IL1 secretion of IFN-treated monocyte cultures could be triggered by suboptimal dosage of endotoxins, unable to induce any IL1 activity in control medium-treated cultures. IFN was highly efficient in this system, since very low concentrations (of the order of 2 units) were effective. Since IFN alone, without endotoxin stimulation, was unable to induce IL1 secretion, the results indicate that IFN is able to activate monocytes, by inducing a potential secretory capable rather than an ongoing IL1 secretion function. The ability of IFN to enhance the IL1 secretory potential of human monocytes may be relevant to the known immunoenhancing effects of IFN preparations and to the pyrogenic effects of IFN administration in patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345180     DOI: 10.1002/eji.1830130602

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  26 in total

1.  Mechanisms of macrophage activation in rheumatoid arthritis: the role of gamma-interferon.

Authors:  M G Ridley; G S Panayi; N S Nicholas; J Murphy
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

2.  Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans.

Authors:  T Mandrup-Poulsen; K Bendtzen; J Nerup; C A Dinarello; M Svenson; J H Nielsen
Journal:  Diabetologia       Date:  1986-01       Impact factor: 10.122

Review 3.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Candida albicans polysaccharide extract (MPPS) and PPD stimulate the production of interleukin-1 and lymphocyte proliferation.

Authors:  G Lombardi; E Piccolella; D Vismara; V Colizzi; G L Asherson
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

Review 5.  Macrophage-directed lymphokines.

Authors:  D Y Liu
Journal:  Surv Immunol Res       Date:  1984

6.  Effect of chelerythrine against endotoxic shock in mice and its modulation of inflammatory mediators in peritoneal macrophages through the modulation of mitogen-activated protein kinase (MAPK) pathway.

Authors:  Weifeng Li; Ting Fan; Yanmin Zhang; Xiaofeng Niu; Wei Xing
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

7.  Acute phase response of serum amyloid A protein and C reactive protein to the common cold and influenza.

Authors:  J T Whicher; R E Chambers; J Higginson; L Nashef; P G Higgins
Journal:  J Clin Pathol       Date:  1985-03       Impact factor: 3.411

8.  Osteoinductive LIM mineralization protein-1 suppresses activation of NF-kappaB and selectively regulates MAPK pathways in pre-osteoclasts.

Authors:  Hui Liu; Maggie Bargouti; Susu Zughaier; Zhaomin Zheng; Yunshan Liu; Sreedhara Sangadala; Scott D Boden; Louisa Titus
Journal:  Bone       Date:  2009-11-18       Impact factor: 4.398

9.  Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection.

Authors:  G Zöhrens; T Armbrust; K H Meyer Zum Büschenfelde; G Ramadori
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

10.  Histiocytosis X. Purified (T6+) cells from bone granuloma produce interleukin 1 and prostaglandin E2 in culture.

Authors:  F Arenzana-Seisdedos; S Barbey; J L Virelizier; M Kornprobst; C Nezelof
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.